SPY765.80+0.02%QQQ737.05+0.07%BTC/USD83,044.18−0.49%DIA514.14+0.02%GLD378.31+0.11%TLT78.69+0.09%
Benzinga

Apimeds Pharmaceuticals Us Inc (APUS) Stock Price, Quote, News & History

APUSAMEX
Trade with Public
Trade with Public
$6.39
-0.86-11.86%
At close: Sep 28, 5:00 PM EST
OverviewNewsEarnings ForecastFinancialsSentimentOwnershipCompareStock Report

Apimeds Pharmaceuticals (APUS) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$6.33
Close
$6.39
Volume / Avg.
858.80K / 2.03M
Day Range
$5.56 - $6.50
52 Wk Range
1.51 - 332.00
Market Cap
$10.94M
P/E Ratio
-
Dividend Yield
-
Exchange
AMEX
RSI
71
Short Interest
1.28%
Days to Cover
1

Recent Apimeds Pharmaceuticals US Inc News

Meta, Everpure, Akamai Technologies, Apimeds Pharmaceuticals and Costco: Why These 5 Stocks Are on Investors' Radars Today

META, P, AKAM, APUS, COST were among the stocks seen trending on Thursday, Sept. 24, 2026.
Shivdeep Dhaliwal

Crude Oil Rises Over 4%; Darden Earnings Miss Views

U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
Avi Kapoor

Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?

Apimeds shares are surging Thursday after its subsidiary MindWave Innovations announced a technology services agreement with AQUAE Holdings.
Henry Khederian

Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000

U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.
Avi Kapoor

Why Veeco Instruments Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

Veeco Instruments Inc (NASDAQ: VECO) rose in pre-market trading after reporting Q1 results and affirming FY26 sales guidance with midpoint above estimates. Other gainers include EZGO, EVC, GCTK, AVTX, OCG, COMP, ALIT, TBH, and SMCI, while losers include ATOM, NWGL, and APUS.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-13.28M
Investing Cash Flow (TTM)
-8.06M
Financing Cash Flow (TTM)
12.88M
Free Cash Flow (TTM)
-13.33M
Capital Expenditure (TTM)
-53.36K
Net Change in Cash (TTM)
-8.46M

Valuation Metrics

Enterprise Value
$25.23M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
0.10
Earnings Yield % (TTM)
-496.28%
Earnings Yield % (FWD)
-
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$70.54

Company Debt

Total Debt
$14.41M
LT Debt
-
LT Debt Issuance (TTM)
$15.65M
LT Debt Repayment (TTM)
-
Total Cash
$278.37K
Debt to Equity
0.14
Issuance of Debt (TTM)
$14.65M
Repayment of Debt (TTM)
-

Key Statistics

Open
$6.33
Close
$6.39
Volume / Avg.
858.80K / 2.03M
Day Range
$5.56 - $6.50
52 Wk Range
1.51 - 332.00
Market Cap
$10.94M
P/E Ratio
-
Dividend Yield
-
Exchange
AMEX
RSI
71
Short Interest
1.28%
Days to Cover
1

About

Sector
Health Care
Industry
Biotechnology
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evalua...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

Q

How do I buy Apimeds Pharmaceuticals (APUS) stock?

A

You can purchase shares of Apimeds Pharmaceuticals (AMEX:APUS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Apimeds Pharmaceuticals (APUS) competitors?

Q

What is the forecast, or price target, for Apimeds Pharmaceuticals (APUS) stock?

A

There is no analysis for Apimeds Pharmaceuticals to provide a consensus price target.

Q

What is the current price for Apimeds Pharmaceuticals (APUS)?

A

The stock price for Apimeds Pharmaceuticals (AMEX: APUS) is $ last updated .

Q

Does Apimeds Pharmaceuticals (APUS) pay a dividend?

A

There are no upcoming dividends for Apimeds Pharmaceuticals.

Q

When is Apimeds Pharmaceuticals (AMEX:APUS) reporting earnings?

A

Apimeds Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Apimeds Pharmaceuticals (APUS) going to split?

A

There is no upcoming split for Apimeds Pharmaceuticals.

Q

What sector and industry does Apimeds Pharmaceuticals (APUS) operate in?

A

Apimeds Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved